CA2135669A1 - Ribavirine servant d'agent protecteur hepatique - Google Patents

Ribavirine servant d'agent protecteur hepatique

Info

Publication number
CA2135669A1
CA2135669A1 CA002135669A CA2135669A CA2135669A1 CA 2135669 A1 CA2135669 A1 CA 2135669A1 CA 002135669 A CA002135669 A CA 002135669A CA 2135669 A CA2135669 A CA 2135669A CA 2135669 A1 CA2135669 A1 CA 2135669A1
Authority
CA
Canada
Prior art keywords
ribavirin
liver
patient
pharmaceutical composition
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002135669A
Other languages
English (en)
Inventor
Nils O. Johannesson
John E. Gait
Gordana Kosutic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Americas Inc
Original Assignee
ICN Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICN Pharmaceuticals Inc filed Critical ICN Pharmaceuticals Inc
Priority to CA002135669A priority Critical patent/CA2135669A1/fr
Publication of CA2135669A1 publication Critical patent/CA2135669A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002135669A 1994-11-10 1994-11-10 Ribavirine servant d'agent protecteur hepatique Abandoned CA2135669A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002135669A CA2135669A1 (fr) 1994-11-10 1994-11-10 Ribavirine servant d'agent protecteur hepatique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002135669A CA2135669A1 (fr) 1994-11-10 1994-11-10 Ribavirine servant d'agent protecteur hepatique

Publications (1)

Publication Number Publication Date
CA2135669A1 true CA2135669A1 (fr) 1996-05-11

Family

ID=4154657

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002135669A Abandoned CA2135669A1 (fr) 1994-11-10 1994-11-10 Ribavirine servant d'agent protecteur hepatique

Country Status (1)

Country Link
CA (1) CA2135669A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032128A1 (fr) * 1997-12-22 1999-07-01 Schering Corporation Forme posologique solide et orale, comprenant de la ribavirine, et son procede de fabrication
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
EP1240899A3 (fr) * 1996-01-23 2004-05-19 Ribapharm, Inc. Régulation de l'expression des cytokines TH1/TH2 par la ribavirine et ses analogues dans des lymphocytes T activés dans le traitement des infections HCV
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
WO2011029868A1 (fr) 2009-09-11 2011-03-17 Ratiopharm Gmbh Formulation pharmaceutique contenant de la ribavirine

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1240899A3 (fr) * 1996-01-23 2004-05-19 Ribapharm, Inc. Régulation de l'expression des cytokines TH1/TH2 par la ribavirine et ses analogues dans des lymphocytes T activés dans le traitement des infections HCV
WO1999032128A1 (fr) * 1997-12-22 1999-07-01 Schering Corporation Forme posologique solide et orale, comprenant de la ribavirine, et son procede de fabrication
US6051252A (en) * 1997-12-22 2000-04-18 Schering Corporation Orally administrable solid dosage form
US6335032B1 (en) 1997-12-22 2002-01-01 Schering Corporation Orally administrable solid dosage form
US6337090B1 (en) 1997-12-22 2002-01-08 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
EP1321147A1 (fr) * 1997-12-22 2003-06-25 Schering Corporation Forme posologique solide comprenant de la ribavirine, pour administration par voie orale, et son procédé de fabrication
AU762826B2 (en) * 1997-12-22 2003-07-03 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
WO2011029868A1 (fr) 2009-09-11 2011-03-17 Ratiopharm Gmbh Formulation pharmaceutique contenant de la ribavirine

Similar Documents

Publication Publication Date Title
WAN et al. Treatment of ocular fungal infections with oral fluconazole
Sobel et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole
Villars et al. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases
US4628063A (en) Antiviral pharmaceutical preparations and methods for their use
Laskin et al. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus
Davidson et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis
US10787502B2 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
Smee et al. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses
Jones et al. Oral ketoconazole: an effective and safe treatment for dermatophytosis
Borok et al. Pityriasis rubra pilaris: further observations of systemic retinoid therapy
KR20050044587A (ko) Ｂ형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도
Amsterdam et al. Suppression of herpes simplex virus infections with oral lithium carbonate—a possible antiviral activity
US4914131A (en) Antiviral pharmaceutical preparations and methods for their use
CA2111837A1 (fr) Composition topique favorisant la cicatrisation des lesions de l'herpes
Higgins et al. Failure to demonstrate synergy between interferon-α and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers
Nikaido et al. A case of allergic bronchopulmonary aspergillosis successfully treated with itraconazole
TWI282735B (en) Combination and pharmaceutical formulation for the treatment of HBV infection
CA1174169A (fr) Tolciclate et tolnaftate administres par voie orale
JP2019011320A (ja) ペマフィブラートを含有する医薬
JPH07106980B2 (ja) ヘルペスウイルスにより引き起された疾患の治療剤
US20250064795A1 (en) Methods of treating coronavirus disease and compounds for same
Sanmano et al. Combination therapy consisting of week pulses of oral terbinafine plus topical application of terbinafine cream in the treatment of onychomycosis
Chipps et al. Effect of omalizumab on healthcare utilization in patients with moderate to severe allergic asthma
Yezdani et al. Comparative Study of Valacyclovir and Acyclovir for the Improves Therapy of Herpes Zoster in an Immunocompetent Adult
USRE32145E (en) Orally active tolciclate .[.(and tolnaftate).].

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued